Physician profile
Hannah E Landers
NPI 1801436142
$3,975.84
in general payments reported to CMS, 2019-2025
26 companies · $1,058 in 2025
The $1,058 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $580 · 2022: $518 · 2023: $916 · 2024: $903 · 2025: $1,058.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,877.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $576.64 | 2021-2025 | Synergy, Avvigo Guidance System, Wolverine Coronary Cutting Balloon |
| Amgen INC. | $506.81 | 2021-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $442.28 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $409.62 | 2021-2025 | Verquvo, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $386.45 | 2021-2025 | Eliquis, Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $355.68 | 2021-2025 | Lifevest |
| Novo Nordisk INC | $310.96 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $203.29 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $163.28 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $161.45 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.81 | 2021-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $44.22 | 2021-2024 | Xarelto |
| Kiniksa Pharmaceuticals International, Plc | $43.49 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $41.62 | 2021 | |
| Scpharmaceuticals INC. | $33.96 | 2023-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $30.66 | 2023-2025 | Andexxa, Wainua |
| Alnylam Pharmaceuticals INC. | $28.60 | 2025 | Amvuttra |
| Astellas Pharma US INC | $26.58 | 2021 | |
| Daiichi Sankyo INC. | $25.26 | 2022 | |
| Csl Behring | $18.23 | 2021 | |
| Impulse Dynamics (USA) INC. | $18.02 | 2023 | Optimizer |
| Chiesi USA, INC. | $15.46 | 2022 | |
| Irhythm Technologies, INC. | $15.45 | 2023 | Zio Xt Patch |
| Amarin Pharma, INC. | $14.85 | 2021 | |
| Philips North America LLC | $14.49 | 2024 | (Cm9) Amb Mon & Diag Und |
| Akcea Therapeutics, INC. | $13.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Landers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.